Novartis’s Tasigna (nilotinib) met its primary endpoint in the first head-to-head comparison with Glivec (imatinib). The company said, Tasigna produced faster and deeper responses than Glivec when given
Novartis’ new phase II results show that the new therapy ACZ885 (canakinumab) is significantly more effective than an injectable corticosteroid at reducing pain and preventing recurrent attacks or
MorphoSys has enter into a new alliance with Daiichi Sankyo in the discovery and development of therapeutic antibodies for hospital-acquired (nosocomial) infections. Daiichi Sankyo becomes MorphoSys’s first collaborator
Ipsen has entered into an agreement under which Ipsen grants exclusive licence rights for Adenuric (febuxostat) to the Menarini Group. Adenuric 80mg and 120mg tablets are indicated for
AFFiRiS’ phase I clinical studies of its two alzheimer’s vaccines AD01 and AD02 met primary endpoints and has demonstrated favourable safety and tolerability profiles. Reportedly, these results trigger
Beneo-Palatinit, a developer, manufacturer and marketer of Isomalt, has introduced galenIQ 981 excipient, which is said to offer ways to improve industrial processing, stability and shelf-life for drug
The FDA has granted 510(k) clearance to Abbott for an antibody cyclic-citrulinated peptide, or anti-CCP assay, to run on the world class systems. The company said that by
US Patent and Trademark Office (USPTO) has awarded US Patent No. 7,592,437 to Prometheus Laboratories (Prometheus). The patent, entitled “Genes Involved in Intestinal Inflammatory Diseases and Use Thereof,”
TechnoVax has received a three-year $2.9m SBIR phase II grant from the National Institutes of Health to further the development of its Virus-Like Particle (VLP)-based vaccine program. Reportedly,
Abbott has completed the $400 million acquisition of privately held eye care company Visiogen, expanding the company’s vision care business with latest intraocular lens (IOL) technology to address
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.